AML
Clinical trials for AML explained in plain language.
Never miss a new study
Get alerted when new AML trials appear
Sign up with your email to follow new studies for AML, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to tame aggressive leukemia
Disease control OngoingThis study is testing a combination of three drugs for adults with a specific type of acute myeloid leukemia (AML) that has returned after treatment or did not respond to initial therapy. The goal is to see if adding a newer targeted drug (gilteritinib) to two existing drugs is s…
Matched conditions: AML
Phase: PHASE2 • Sponsor: Centre Antoine Lacassagne • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New attack plan for blood Cancer's comeback
Disease control OngoingThis study is testing a combination of two drugs (venetoclax and azacitidine) along with an infusion of immune cells from the original stem cell donor. It is for adults whose myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) has come back after a stem cell transplant…
Matched conditions: AML
Phase: PHASE1, PHASE2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Scientists test new strategy to stop Leukemia's return
Disease control OngoingThis study is testing a new, personalized approach to treat acute myeloid leukemia (AML) when it starts to come back. Doctors will use genetic information from a patient's cancer to choose specific drug combinations, aiming to attack the disease early based on tiny traces of left…
Matched conditions: AML
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 18, 2026 18:25 UTC
-
New drug targets hidden leukemia cells in patients who failed standard care
Disease control OngoingThis study tests an experimental drug called vibecotamab in adults with two types of blood cancer: acute myeloid leukemia (AML) that still shows tiny amounts of cancer after treatment, and myelodysplastic syndrome (MDS) that has stopped responding to standard medications. The goa…
Matched conditions: AML
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 16, 2026 15:24 UTC